Glenn Dranoff

This inventor holds 34 USPTO granted patents and 26 published patent applications and 10 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Dana-Farber-Cancer Institute Inc., Harvard College, Novartis Ag. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Glenn Dranoff. Retrieved from https://idiyas.com/inventor/glenn-dranoff

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 34 (Patent Applications = 26)

% Patents Active = 91.2

EPO Patents = 10 (Patent Applications = 32)

Average Co-Inventor Count = 4.2

ph-index = 9

Forward Citations = 186(Granted Patents)

Location History:

Cambridge, MA (US) (2018)
Lexington, MA (US) (2007 - 2023)
Sudbury, MA (US) (2016 - 2024)

Company Filing History:

29 out of 1,268

Dana-Farber-Cancer Institute Inc.

The General Hospital Corporation

patents

5. 1 out of 1,073

Children's Medical Center Corporation

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Cancer Immunotherapy

Antibody Molecules

Vaccine Compositions

Chimeric Antigen Receptors

Tumor Suppressor

Immunomodulation

NKG2D Pathway

IAP Inhibitors

Therapeutic Peptides

Tumor Antigens

TLR Agonists

Combination Therapies

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE50908 - VACCINE COMPOSITIONS AND METHODS FOR RESTORING NKG2D PATHWAY FUNCTION AGAINST CANCERS (2026-06-09),

2. 12630633 - ANTIBODY MOLECULES TO PD-1 AND USES THEREOF (2026-05-19),

3. 12630604 - METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS (2026-05-19),

4. 12600777 - COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO LAG-3 (2026-04-14),

5. 12383601 - Chimeric antigen receptors and uses thereof (2025-08-12),

6. 11998593 - Combination vaccine devices and methods of killing cancer cells (2024-06-04),

7. 11851472 - NKG2D-IG fusion protein for cancer immunotherapy (2023-12-26),

8. 11624093 - Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response (2023-04-11),

9. 11597934 - Methods and compositions for reducing immunosuppression by tumor cells (2023-03-07),

10. 11382905 - Immunomodulation by IAP inhibitors (2022-07-12),

11. 10876120 - Methods and compositions for reducing immunosupression by tumor cells (2020-12-29),

12. 10865233 - NKG2D-fc for immunotherapy (2020-12-15),

13. 10865232 - NKG2D-IG fusion protein for cancer immunotherapy (2020-12-15),

14. 10851165 - Antibody molecules to PD-L1 and methods of treating cancer (2020-12-01),

15. 10793633 - Therapeutic peptides (2020-10-06),

Title: The Innovative Journey of Glenn Dranoff

Introduction: Glenn Dranoff, a renowned inventor hailing from Sudbury, MA (US), has made significant contributions to the field of innovations and patents with his groundbreaking work.

Latest Patents: Dranoff's latest patents showcase his expertise in the development of cutting-edge medical devices aimed at revolutionizing the healthcare industry. His inventions focus on improving patient outcomes and enhancing medical procedures.

Career Highlights: With a distinguished career spanning over two decades, Glenn Dranoff has established himself as a pioneer in the field of medical technology. His innovative solutions have garnered international recognition and have been instrumental in shaping the future of healthcare.

Collaborations: Throughout his career, Dranoff has collaborated with leading medical institutions, research organizations, and industry experts to bring his inventions to life. His partnerships have been crucial in driving forward his vision of creating impactful and transformative technologies.

Conclusion: Glenn Dranoff's relentless passion for innovation and his unwavering commitment to excellence have solidified his position as a trailblazer in the world of inventions. His remarkable contributions continue to inspire future generations of inventors and shape the landscape of technological advancements.

Profile summary based on public USPTO records.